Abstract: There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a test sample from the subject selected from the group consisting of DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAAQ125. CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56; and (b) comparing expression of the at least 3 genes in the test sample with reference expression levels of the at least 3 genes from control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse survival.
Type:
Grant
Filed:
February 6, 2017
Date of Patent:
September 7, 2021
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Jean Wang, John Dick, Stanley Ng, Mark Minden, Amanda Mitchell, Weihsu Chen, Peter Zandstra, James Kennedy
Abstract: The present application relates to a detection kit for genotypes capable of confirming cross contamination that may occur in a banking process of a patient-derived xenograft model or cell-derived xenograft model and a method for determining cross contamination using the same. According to the present disclosure, it is possible to determine all of cross contamination of mouse related genes, have high detection sensitivity and specificity to be close to 100%, rapidly examine the contamination, and be very useful in predicting mouse contamination. Therefore, according to the present disclosure, cross contamination of genes related with the human and the mouse is predicted in advance to be applied to evaluation of anticancer drug efficacy using a patient-derived xenograft model or cell-derived xenograft model and contribute to cell banks using the patient-derived xenograft model or cell-derived xenograft model, and as a result, the present disclosure is very useful in a medical industry.
Abstract: A method for preparing a ratiometric electrochemical miR3123 aptasensor based on a copper-based metal-organic framework (Cu-MOF) composite doped with black phosphorus nanosheets (BPNSs) and thionine (TH) is provided. TH/Cu-MOF is prepared by reacting TH with Cu-MOF precursor, and BPNSs/TH/Cu-MOF is prepared by drop coating the BPNSs and drop coated onto an electrode. A ferrocene (Fc)-labeled single-stranded DNA aptamer is adsorbed on the BPNSs to prepare aptamer-BPNSs/TH/Cu-MOF. Target molecule miR3123 is bonded with the single-stranded DNA aptamer Fc-DNA, Fc-DNA is forced to escape from the BPNSs. Electrochemical signals of Fc are, therefore, weakened while TH signals are slightly affected. The ratiometric electrochemical miR3123 aptasensor is constructed by fitting a linear relationship between peak current intensity ratios IFc/ITH and concentrations of the miR3123.
Abstract: Genetic characterisation of closely related inbreds is at present only possible by means of whole genome sequencing. This is however a time-consuming process. The invention addresses the need for a method to differentiate between closely related substrains of inbreds. The method involves analysis of at least two tandem repeat loci per chromosome. Said tandem repeat loci are characterised by high mutation rates. The amplified fragments are subsequently used to determine the alleles that are present at each amplified locus within the DNA sample.
Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.
Type:
Grant
Filed:
June 6, 2013
Date of Patent:
August 17, 2021
Assignees:
INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Abstract: The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.
Type:
Grant
Filed:
February 28, 2020
Date of Patent:
August 10, 2021
Assignee:
Mercy BioAnalytics, Inc.
Inventors:
Joseph Charles Sedlak, Laura Teresa Bortolin, Daniel Parker Salem
Abstract: The present invention discloses a method of detecting the presence of mutated genes, mRNAs or microRNAs in a subject. The method comprises the following steps: (1) Provide a body fluid sample containing cells, circulating tumor cells (CTCs), and/or extracellular vesicles (EVs); and use an analyzer having overhang molecular beacons to measure fluorescence signals generated by interactions between the body fluid sample and the overhang molecular beacons, so as to detect the presence of the mutated genes, mRNAs or microRNA. Furthermore, a biochip comprising a gold coating substrate and tethered lipoplex nanoparticles encapsulating the overhang molecular beacons is also provided in the invention.
Type:
Grant
Filed:
January 25, 2018
Date of Patent:
August 10, 2021
Assignee:
SPOT BIOSYSTEMS LTD.
Inventors:
Ly James Lee, Jiaming Hu, Kwang Joo Kwak
Abstract: The present invention relates to methods and systems for assessing the overall risk of a human female subject for developing a breast cancer phenotype. In particular, the present invention relates to combining clinical risk assessment and genetic risk assessment to improve risk analysis.
Abstract: This document provides methods and materials involved in assessing cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) having ER?/PgR?/HER2? cancer cells is likely to have a favorable or unfavorable outcome and/or is likely to respond a cancer treatment that includes a PD-1 inhibitor and/or PD-L1 inhibitor in combination with a JAK2 inhibitor are provided. Methods and materials involved in treating mammals having ER?/PgR?/HER2? cancer (e.g., ER?/PgR?/HER2? breast cancer) by administering a PD-1 inhibitor and/or PD-L1 inhibitor in combination with a JAK2 inhibitor also are provided.
Type:
Grant
Filed:
March 16, 2016
Date of Patent:
July 13, 2021
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Barbara A. Pockaj, Michael T. Barrett, Mitesh J. Borad, Karen S. Anderson, Ramesh K. Ramanathan
Abstract: The present invention relates to a method for the diagnosis/prognosis of a septic syndrome based on a biological sample from a patient, characterized in that it comprises the following steps: a. biological material is extracted from the biological sample, b. the biological material is brought into contact with at least one specific reagent that is selected from specific reagents for the target genes with a nucleic sequence having any one of SEQ ID Nos 1 to 28; c. the expression of at least one of said target genes is determined.
Abstract: The present invention discloses methods, kits, and apparatus as well as reagents and compositions associated therewith for deriving an indicator for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. Also disclosed is a biomarker signature for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. The present invention further discloses methods, kits and apparatus, as well as reagents and compositions associated therewith, for identifying biomarkers for use in a biomarker signature.
Type:
Grant
Filed:
February 6, 2015
Date of Patent:
June 29, 2021
Assignee:
ImmuneXpress Pty Ltd
Inventors:
Richard Bruce Brandon, Leo Charles McHugh
Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.
Abstract: Methods of identifying potential skin moisturizing actives for the treatment of dry skin and method of formulating a moisturizing skin care composition using actives identified by the method. Moisturizing agents can be identified by comparing the transcriptional profile of a skin tissue sample contacted by a test agent to a negative or positive control to determine if the regulation of certain genes corresponds to the appropriate direction of regulation indicated by the control. Agents identified as skin moisturizing agents can then be incorporated into a skin moisturizing composition.
Type:
Grant
Filed:
May 9, 2017
Date of Patent:
June 15, 2021
Assignee:
The Procter & Gamble Company
Inventors:
Qing Stella, Michael Keith Robinson, Kevin John Mills
Abstract: The use of PHGDH as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of PHGDH modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring PHGDH expression and/or activity.
Type:
Grant
Filed:
July 8, 2016
Date of Patent:
June 15, 2021
Assignee:
BerGenBio ASA
Inventors:
Monica Hellesoy, Linn Hodneland Nilsson, David Robert Micklem
Abstract: The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine, isolating corresponding mRNA, and analyzing expression patterns in order to diagnose and treat various urothelial cancers. In particular, various expression patterns are analyzed through a unique diagnostic formula.
Type:
Grant
Filed:
August 30, 2016
Date of Patent:
June 8, 2021
Assignees:
Showa Denko Materials Co., Ltd., Showa Denko Materials (America), Inc., City of Sapporo
Inventors:
Taku Murakami, Cindy M. Yamamoto, Masato Mitsuhashi, Hiroshi Harada
Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.
Type:
Grant
Filed:
December 11, 2017
Date of Patent:
June 1, 2021
Assignee:
GENENTECH, INC.
Inventors:
Mark Lackner, Lukas C. Amler, Guy Cavet, Carol O'Brien, Ajay Pandita
Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoinflammatory diseases such as psoriasis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
Abstract: The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d'Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent.
Type:
Grant
Filed:
July 29, 2015
Date of Patent:
May 18, 2021
Assignee:
Wellmarker Bio Co., Ltd.
Inventors:
Tae Won Kim, Dong Hoon Jin, Seung Woo Hong, Jai Hee Moon, Jae Sik Shin, Seung Mi Kim, Dae Hee Lee, Eun Young Lee, Seul Lee, Yong Sang Hong
Abstract: A group of molecular biomarkers having the genes SLC35D3, POSTN, KLK6 and MUC2 can be used in objective and quantitative methods for the classification, prediction of prognosis and for guiding treatment decisions of a subject with colorectal cancer. More specifically, a method for determining the metastatic potential and/or tumor aggressiveness of a colorectal cancer in a subject can include determining the gene expression levels of genes SLC35D3, POSTN, KLK6 and/or MUC2 in a regional lymph node, a primary intestinal tumor, blood, or feces sample obtained from the subject.
Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
Type:
Grant
Filed:
June 3, 2016
Date of Patent:
March 23, 2021
Assignees:
Millennium Pharmaceuticals, Inc., The General Hospital Corporation
Inventors:
Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Lightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman